Solutions for CAR-T Cell Therapy, Adoptive Cell Therapy Discovery and Development

Chimeric antigen receptor T cell-based therapy, using engineered T cells to fight cancer, is a transformative technology like gene therapy or regenerative medicine that may forever change the landscape of medicine.  CAR-T cell-based therapy uses immune cells – either the patient’s own (autologous) or from a donor (allogeneic) – that have been genetically transformed and are then infused into the patient to bind to cancer cells and destroy them.

At Sartorius, we know every detail of the CAR-T development workflow counts. We believe your ambition is to achieve the highest quality results every day: results that are reproducible, publishable, and actionable, resulting in breakthrough therapy. That’s why we strive to provide innovative solutions, from biomarker identification to production.  We want to help you develop the safest CAR-T product, with the highest levels of productivity. Our goal is to support you at every step of the translational research process, and ensure that you never compromise your ambition.

Recent FDA & EMA approvals of CAR-T cell therapies (Kymriah®, Yescarta®) have revolutionized the available therapeutic landscape and given new hope to patients, the medical field, and the research community. To achieve the necessary efficacy and safety for approval of a CAR-T cell therapy, researchers must understand their model systems, identify potential therapeutic targets, and evaluate corresponding hits at an unprecedented level, as early as possible.

The discovery and development process has many steps during which results must remain uncompromised, such as:

  • Isolation of tumor infiltrating lymphocytes (TILs) or circulating T cells
  • Early in vitro assays deploying specific tumor cell models and understanding immune cell activation
  • CAR-T vector choice for viral gene transfer
  • Imaging and flow cytometry to assess biological responses
  • In vivo studies in animals
  • Clinical trials involving human subjects 

It starts with basic foundational elements like proper pipetting and liquid-handling technique, aseptic cell culture handling, expansion under optimal conditions, and confidence that cultures are free from contaminating agents such as mycoplasma. False positive and false negative results, as well as random or uncontrollable artifacts, can significantly decelerate the discovery and development process, potentially hindering novel insights. Your work requires equipment, technology, and assays specifically developed to deliver safety, speed, and productivity.

Sartorius has developed comprehensive and complementary solutions to help you trust your therapy. Read below to learn what solutions are right for your CAR-T therapy discovery and development efforts.

How Sartorius accelerates and provides confidence in your CAR-T discovery & development

  • Safety: in-depth sample analysis, fast and precise viral vector quantification, rapid detection of contaminants
  • Speed: rapid sample acquisition, no-wash assays, optimized reagents, advanced analysis software
  • Productivity: multiparametric measurement of T-cell dependent cytotoxicity, CAR-T cell phenotype, CAR transduction and activation
  • Biologically relevant results: extension of 2D assays to 3D cultures, assays for both adherent (dissociated solid tumor cells) and non-adherent cell lines
  • Cell characterization & QA/QC: continuous phenotypic & functional analysis over time, under aseptic conditions


From Boutique to Global: Chimeric Antigen Receptor T-Cells as a Model for Clinical Development and Commercialization

Register now to listen to Univ. of Pennsylvania's Dr. Bruce Levine as he discusses the science of CAR T-cells and their huge global impact.

Register now


Gaining Critical Product Characterization Insights for CAR T Cell Therapy Research

Join a roundtable webinar reviewing the state-of-the-art in cell analysis and its specific utility in the CAR T cell therapy space as it seeks to advance beyond haematological malignancies and into the solid tumor space.

Register now

NEW Editorial Article: Potential of CAR-T Therapies for Solid Tumors

Download now

Discover Our Solutions

By maximizing the probability of success and minimizing failure rates throughout the R&D process, we ultimately help decrease overall cost and time from bench to bedside.

Whether considering autologous or allogeneic CAR-T therapies, numerous challenges present themselves, among them target antigen selection, on-/off-target screening, CAR delivery, appropriate tumor cell lines, animal models and clinical relevance, tumor heterogeneity, immune escape, expansion and persistence, neurotoxicity, and cytokine release syndrome.

To address this high degree of complexity and the inherently ever-evolving nature of cancer biology, Sartorius supports and enables scientists in their quest to develop the next generation of CAR-T therapies by providing solutions to increase speed and throughput, decrease costs, and allow validation of results via multiparametric methods. We improve product safety and increase trust in the global body of knowledge by providing scientific instrumentation (e.g. flow cytometers, imagers) and equipment and consumables (pipettes & tips, detection kits, and more) of the highest quality and peak functionality.

Discover how Sartorius can help you trust your therapy and have confidence throughout your CAR-T development process with a portfolio that ranges from basic foundational tools, such as pipettes and mycoplasma detection kits, to elegant and intricate technologies, such as real-time non-perturbing cell analysis, flow-based CAR-T vector characterization requiring minimal sample volumes, and GMP-compliant cell expansion platforms.

IncuCyte® Live-Cell Analysis System

Enables real-time, automated imaging and analysis of CAR-T cell homing (chemotaxis), activation and function, directly from the incubator over...

Learn More

Intellicyt® iQue3

A high throughput, CAR-T cell analysis platform for rapidly profiling cell phenotype and function in cell therapy workflows.

Learn More


Your pipette can be an extension of your hand, and is one of the most used (and most personal) tools in your laboratory. Manual and electronic...

Learn More

MYCAP® CCX Cell Expansion System

Combining integral tubing for aseptic fluid transfer and our unique gas exchange cartridge to support cell growth means you can expand cultures...

Learn More

Microsart® ATMP Rapid Real-time PCR Mycoplasma/Bacterial...

Providing fast contaminant detection during CAR-T discovery & development for increased safety. Rapid, highly specific & sensitive...

Learn More

Virus Counter® Platform

CAR-T viral vector quantification has never been easier or faster. Assess the quality and quantity of viral materials with minimal sample...

Learn More

BIOSTAT RM TX Bioreactor

Enables ex vivo expansion of autologous T-cells, while facilitating process development.

Learn More

CAR-T Research Resources

Brochure: Innovative Solutions to Advance CAR-T Discovery and Development | July 2019

PDF | 3.5 MB



CAR T-cell Therapy and Bispecific Antibodies: Frontiers in Cancer Immunotherapy

Register now to watch a panel of experts discuss the design, development, and success of CAR T-cell therapy and bispecific antibodies and the potential these therapeutics hold in the fight against various tumor types.

Register now

Request More Information

Are you interested in receiving more information on cell analysis instruments for your research?

Are you looking to purchase cell analysis equipment for your lab?

What other products/areas are of interest (check all that apply):

How can we assist you with these products?